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Noninvasive Methods for Measuring DNA
Alkylation in Experimental Animals and
Humans
by David E.G. Shuker,1 Virginie Prevost,'
Marlin D. Friesen,1 and Helmut Bartsch'
AlkylpurinesareliberatedfromalkylatedDNAbyglycosylaserepairenzymesand, in mostcases,excreted in
urinewithoutfurthermetabolism. Thisphenomenonformsthebasisofnoninvasive methods to measure DNA
alkylation in vivo. In the case ofmethyl adducts, such as 7-methylguanine (7-MeGua), natural backgrounds
existdue to RNAturnover. However, deuterated (d3) methylatingagents orprecursors give rise to d3-7-MeGua
and d3-3-methyladenine (3-MeAde), which can be readily quantitated using gas chromatography-mass
spectrometry (GC-MS).Adeuteratedprobe drug,such asd6-aminopyrine, can be used to measure endogenous
nitrosation levels in experimental animals. In contrast, for higher alkyl homologues ofalkylpurines, natural
backgrounds are low or nonexistent and can be directly measured by GC-MS using stable isotope labeled
internal standards. For example, increased levels of urinary 3-ethyladenine were observed in cigarette
smokers. Due to recent advances in analytical methodology, notably immunoaffinity cleanup of urine,
measurements ofexcreted DNA adducts can be used in studies in human populations exposed to low levels of
alkylating carcinogens.
Introduction
Alkylating carcinogens react with DNA at most, if not
all, of the nucleophilic nitrogen and oxygen centers. The
majorsitesofreaction are atthe N7and 06 ofguanine, N3
ofadenine, and 0- ofthephosphate residues (1). Inrecent
years, a number of efficient repair systems have been
discovered that can remove various carcinogen-DNA
adducts (2). The glycosylases liberate the alkylatedpurine
base, leaving an apurinic site that is subsequently
repaired. In contrast, alkyltransferases mediate the
transferofthealkyl groupto areceptorcysteineresiduein
the repair protein, thus restoring the original base.
In many cases, alkylpurines that are liberated by
glycosylases are excretedintactinurine, as these adducts
do not appear to be substrates for catabolic enzymes
[reviewed by Shuker and Farmer (37)]. These observa-
tions suggested that it ought to be possible to determine
the level ofmodification ofDNA at all sites by measuring
alkylpurines in urine. Interestingly, Craddock and Magee
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(4) found that rats whose DNA had been specifically
labeled with 14C and which were subsequently treated
with 3H-labeled nitrosodimethylamine (NDMA), excreted
[3H,14C]-7-methylguanine (7-MeGua), thus demonstrat-
ing a direct link between DNA methylation and urinary
excretion ofmethylated adducts. Recently, Gombar et al.,
(5) showed that [14C]7-MeGua was excreted by rats that
had been treated with [14C]aminopyrine (AP) and nitrite,
a combination known to result in endogenous synthesis of
[14C]NDMA. In addition, it was shown that there was an
excellent correlation between DNA methylation in liver
(targetorgan) andurinary excretion of7-MeGua and that
the urinary adduct was readily detectable at low doses of
AP and nitritewhere DNAmethylationwas undetectable.
In view of the natural occurrence of certain urinary
methylpurines asaresultoftheturnoverofRNA,inwhich
certain methylated nucleosides are present at relatively
high levels and are crucial to the normal functioning of
RNA [for example, 7-methylguanosine is present in the
end-cappingregion oftRNAs (6)], most studies onmethy-
lation have been carried out using radioactively labeled
carcinogens. Although this is clearlyuseful in experimen-
tal studies, it is impracticable and ethically unacceptable
(other than in exceptional circumstances such as in the
development ofnewdrugs) to use radiolabeled compounds
in human volunteers. For this reason, a number ofgroups
have used stable isotope-labeled methylating agents andSHUKER ET AL.
precursors, and this area is reviewed here. The problems
outlined above are not as greatwhen alkylating exposures
other than methylation, which is a frequently encountered
biochemical process, are studied. For example, adducts
from aflatoxin B1 and benzo[a]pyrene are sufficiently
characteristic thatitis extremelyunlikely thattheywould
be formed by any other route than by exposure to the
carcinogen. Recent results on the development ofnoninva-
sive methods to measure DNA alkylation in vivo are
presented in this paper.
Excretion of d3-Methyl Adducts after
Administration of d3-Methylating
Agents or Precursors
Stable isotope labelling (typically with 2H[d], 13C, or
15N) of alkylating carcinogens or precursors not only
allows metabolic pathways to be studied using mass spec-
trometry but also offers the potential for use in human
studies. The transfer of intact d3-methyl groups from
hexadeuterated NDMA to N7 of guanine in DNA and
RNAinvivowas demonstrated firstby Lijinsky et al. [(7)
Fig. 1]. Similar reactions were shown for N-methyl-N'-
nitro-N-nitroso-guanidine (8) and 5-(3-methyl-1-triaze-
no)-imidazo-4-carboxamide (9).
More recently, the excretion ofd3-7-MeGuawas used to
study the in vivo nitrosation and alkylating activity of
potentially nitrosatable drugs containing N-d3-methyl
functions. Thus, coadministration of d6-aminopyrine (d6-
AP) and nitrite to rats resulted in dose-dependent excre-
tion ofd3-7-MeGua, whereas administration ofd6-AP did
notgive detectable levels ofdeuterated adduct(10). Inrats,
Farmer et al. (11) found that d3-7-MeGua was excreted in
urine after treatment with d3-methylcyclohexylnitrosa-
mine (d3-MNCA), which is the nitrosation product of the
deuterated analogue ofthe drug bromhexine. However, in
human volunteers who received a clinically used dose of
d3-bromhexine, no excretion ofd3-7-MeGuawas observed,
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which suggeststhatendogenousnitrosation ofthis drug,if
it happens at all, occurs to a very low extent (12).
7-MeGuaispresentinurine as aresultofRNAturnover
atlevels thatinterfere with the determination oflowlevels
ofd3-7-MeGua. This interference is due to the presence of
natural isotopes (notably, 13C) that contribute to the M+
+ 3 peak, and this sets apractical limitofdetection thatis
much higher than could be obtained by the mass spec-
trometric methods currently available. This problem can
be circumvented by choosing an excreted methyl adduct
forwhich the naturalurinarybackground is lowornonexi-
stent. This criterionismetby3-methyladenine (3-MeAde),
which is present in human and rat urine at 0.14% and
0.12%, respectively, ofthe levels of7-MeGua (13). Asimilar
dose-response relationship to that described above for
urinary d3-7-MeGua was seen for the excretion of d3-3-
MeAde in rats after coadministration of combinations of
d6-AP and nitrite (13). These results, in combination with
recent improvements in analytical methodology using
immunoaffinity purification of3-MeAde (14), suggest that
d6-AP could be a useful probe drug for studies on
endogenous nitrosation in experimental animals (AP can-
notbe used as aprobe drugin humans due to its toxicity).
Studies arecurrentlyunderwayin ourlaboratory to evalu-
ate the role ofparasitic infections in endogenous nitrosa-
tion using d6-AP in experimental models.
Urinary 3-Alkyladenines as Markers of
DNA Alkylation in Humans.
As described in the previous section, the major DNA
adducts formed from methylating agents are repaired by
glycosylases, resulting in the formation ofmethylpurines,
which are subsequently excreted in urine. These observa-
tions appear to be applicable to higher alkyl homologues
and are summarized in Figure 2. The rationale for using
3-alkyladenines (3-alkAde), in particular, as noninvasive
markers for DNA alkylation in vivo has been described
recently (13). Immunoaffinity columns were prepared
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FIGURE 1. Trideutero(d)methylation of guanine in DNA by d6-
nitrosodimethylamine. Note the conservation of the three deuterium
atoms via the intermediate d3-methyldiazonium ion.
FIGURE 2. Summaryoftheformation andfate ofthemajorDNAadducts
derived from alkylating carcinogens (Alk-X). AP, apurinic sites; alk-AT,
alkylated alkyltransferase protein.
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using a monoclonal antibody that cross-reacts with a
number of different 3-alkAde (alkyl = C1-C7) and were
used to selectivelyextracttheseadducts fromurinebefore
GC-MS analysis (15). Usingthis methodologyitwas dem-
onstrated that a) 3-alkAde such as 3-MeAde, 3-EtAde,
and 3-HOEtAde were excreted essentially unchanged in
humans (3-BzAde,incontrast, appearedtoundergoexten-
sive metabolism) and b) "background" levels of3-alkAde,
otherthan 3-MeAde, wereprogressivelymuchless depen-
dent on diet as the molecular weight of the alkyl group
increased (which is probably related to the decreasing
likelihood of natural sources of higher molecular weight
3-alkAde compared to 3-MeAde).
Thelowornonexistentbackgrounds ofsome3-alkAdein
human urine has allowed studies to be carried out in
humans exposed toenvironmental carcinogens. Forexam-
ple, 3-ethyladenine is excreted in urine of cigarette
smokers at readily detectable levels, which correlate very
well with tobacco consumption (16). Studies currently
underway in our laboratory also include the measurement
of characteristic 3-alkAde in urine of cancer patients
treated with certain chloroethylnitrosoureas.
Conclusions
Inthisbriefsummaryofrecentprogress onthedevelop-
ment and use ofnoninvasive methods formeasuringexpo-
sure to alkylating carcinogens, two main approaches have
been described: the use ofdeuterium-labeled methylating
carcinogens or precursors in studies ofDNAmethylation
in vivo and the measurement of urinary 3-alkAde as
markers ofDNAalkylation. Thesemethodshavebenefited
from recent advances in analytical methodology, notably,
the use of immunoaffinity purification of DNA adducts
from urine in combination with low resolution gas
chromatography-mass spectrometry, which enables their
use in studies in human populations exposed to low levels
ofalkylating carcinogens.
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